Everest Medicines
↗Shanghai, China
Everest Medicines is a leading biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of novel or differentiated therapies and vaccines. The company focuses on addressing critical unmet medical needs in the Asia-Pacific markets, particularly in Greater China, across four core therapeutic areas: autoimmune diseases, oncology, critical care, and cardiovascular, kidney, and metabolic (CKM) diseases.
Founded in 2017, the company has transitioned from a successful in-licensing model to a 'dual-engine' strategy that combines strategic global partnerships with in-house R&D. Everest operates a commercial-scale manufacturing facility in Jiashan, China, and has built a robust commercialization platform anchored by blockbuster assets like Nefecon and Velsipity.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$100M-$150M
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$1.55B (Recent 2025 share placement)
Investors:CBC Group, Ping An Fund Management, ICBC UBS Asset Management, Janus Henderson Investors, Adage Capital Partners
STOCK
Exchange:HKEX
Ticker:1952.HK
Market Cap:$1.71B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mRNA, mAb, ADC, In vivo CAR-T
Active Trials:15
Trial Phases:Phase 1: 4 | Phase 2: 5 | Phase 3: 6
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:Everest Medicines (Singapore) Pte. Limited, Everstar Medicine (US) Limited, Everest Medicines (China) Co., Ltd.
Key Partnerships:Hasten Biopharmaceutical (Commercialization and Licensing), I-Mab (Strategic Equity and Oncology Collaboration), Micot (Exclusive License for MT1013), Calliditas Therapeutics (Nefecon license), Pfizer/Arena (Etrasimod license)
COMPETITION
Position:Leader
Competitors:Abbisko Cayman, Lepu Biopharma, Keymed Biosciences, Ascentage Pharma, Sumitomo Pharma
LEADERSHIP
Key Executives:
Rogers Yongqing Luo - CEO
Yifang Wu - Chairman
Ian Woo - President & CFO
Scientific Founders:CBC Group (Founding Investor)
Board Members:Wei Fu, Yifang Wu, Rogers Yongqing Luo, Ian Woo, Yifan Li, Shidong Jiang
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Everest Medicines. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.